Agios to present new data on mitapivat and tebapivat in rare blood disorders at 66th ash annual meeting and exposition

– results from phase 3 energize-t study of mitapivat in transfusion-dependent thalassemia will be presented in oral session – – tebapivat phase 1 data in sickle cell disease and phase 2b trial-in-progress update in lower-risk myelodysplastic syndromes will be presented and published – – live and webcast investor event with agios leadership and medical experts will be hosted onsite on monday, december 9 – cambridge, mass., nov. 05, 2024 (globe newswire) -- agios pharmaceuticals, inc. (nasdaq: agio), a leader in cellular metabolism and pyruvate kinase (pk) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (ag-946), the company's pk activators, will be featured in oral and poster presentations during the 66th american society of hematology (ash) annual meeting and exposition in san diego, california from december 7-10, 2024.
ASH Ratings Summary
ASH Quant Ranking